Cargando…

Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases

There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coorey, Craig Peter, Phua, Elaine, Chou, Angela, Shen, Yvonne, Mather, Amanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710461/ https://www.ncbi.nlm.nih.gov/pubmed/36465571 http://dx.doi.org/10.1159/000525737

Ejemplares similares

Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
por: Ali, Azhar, et al.
Publicado: (2022)

Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination
por: Robichaud, Julie, et al.
Publicado: (2021)

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine
por: Clayton-Chubb, Daniel, et al.
Publicado: (2021)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
por: Teh, Natalie, et al.
Publicado: (2021)

Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
por: Lee, Hyo Jin, et al.
Publicado: (2023)

Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination
por: Waraich, Ammar, et al.
Publicado: (2021)

Syndrome de fuite capillaire systémique après l’administration du vaccin ChAdOx1 nCOV-19 (Oxford–AstraZeneca)
por: Robichaud, Julie, et al.
Publicado: (2021)

Bilateral adrenal haemorrhage with renal infarction after ChAdOx1 nCoV-19 AstraZeneca vaccination
por: Tha, Tun, et al.
Publicado: (2022)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
por: Mikołajczyk, Marek, et al.
Publicado: (2022)

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Varona, Jose F., et al.
Publicado: (2021)

To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review
por: Mohamed Hussein, Aliae A. R., et al.
Publicado: (2022)

Cerebral venous sinus thrombosis following ChAdOx1 nCoV-19 AstraZeneca COVID-19 vaccine
por: Sharma, Shyam S, et al.
Publicado: (2023)

Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
por: Al Rawahi, Bader, et al.
Publicado: (2021)

Parsonage-Turner Syndrome Following Covishield (AstraZeneca ChAdOx1 nCoV-19) Vaccination: A Case Report
por: Lakkireddy, Maheshwar, et al.
Publicado: (2022)

Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination: A report of three cases and review of the literature
por: Abbott, Molly G., et al.
Publicado: (2022)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
por: Ali, Syed B., et al.
Publicado: (2022)

Superficial Thrombophlebitis of the Penis following AstraZeneca ChAdOx1-S Vaccination: A Rare Venous Thromboembolic Complication
por: Winston, Joshua, et al.
Publicado: (2022)

Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia
por: Jones, Melissa, et al.
Publicado: (2021)

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
por: Pottegård, Anton, et al.
Publicado: (2021)

Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia
por: Gordon, Sally F., et al.
Publicado: (2021)

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023)

The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
por: Tran, Huyen, et al.
Publicado: (2022)

Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1
por: Alzaidi, Areej Awad, et al.
Publicado: (2023)

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S)
por: Kim, Chanhee, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
por: Pattni, Karan, et al.
Publicado: (2022)

Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia
por: MacIntyre, Chandini Raina, et al.
Publicado: (2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021)

Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022)

Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients
por: Callaghan, Chris J., et al.
Publicado: (2022)

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study
por: Aldali, Jehad, et al.
Publicado: (2023)

Pregnant and Breastfeeding Mothers Who Have Received the ChAdOx1 AstraZeneca COVID-19 Vaccine May Have Infants with an Increased Risk of Zinc Insufficiency and SCID Disease
por: Ahmed, Amr, et al.
Publicado: (2023)

Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)

Le vaccin AstraZeneca-Oxford sur le bureau de l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Monoarthritis induced by the Oxford-AstraZeneca(R) SARS-CoV-2 vaccine
por: Schoenardie, Bruna Ossanai, et al.
Publicado: (2022)

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers
por: Chau, Nguyen Van Vinh, et al.
Publicado: (2022)

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
por: Garnier, Matthieu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gt31g7ip40hliedus42ta54caf